HUGO-LAb™ Fully Human Antibody Library
Explore Cyagen’s HUGO-LAb™ fully human antibody library with ready-to-access molecules for mAb, bispecific, ADC, TCE, in vivo CAR-T and CNS drug development.
Accelerate Antibody Development with Ready-to-Access Fully Human Molecules
HUGO-LAb™ is designed to reduce the time and complexity between target selection and therapeutic molecule development by providing ready-to-access fully human antibody candidates across high-value therapeutic areas.
Fully Human Antibodies
Built on the established HUGO-Ab™ fully human antibody mouse
platform, HUGO-LAb™ provides in vivo-selected fully human sequences, eliminating conventional
humanization steps and helping reduce potential immunogenicity risk.
Ready-to-Access Candidates
Access characterized antibody candidates with supporting target and
molecular data to bypass lengthy early-stage screening and accelerate target validation.
Built for Multiple Modalities
Fully human mAbs, common light-chain antibodies, and single-domain
antibodies support bispecifics, multispecifics, ADCs, and in vivo CAR therapies.
Explore the HUGO-LAb™ Target Library
Search HUGO-LAb™ antibody molecules by target and therapeutic area to identify potential building blocks for
your therapeutic program.
| Target | Therapeutic Area | Developable Modality | Indication | Action |
|---|---|---|---|---|
| {{ item.target }} | {{ item.area }} | {{ item.modality }} | {{ item.indication }} |
Next Page
INTEGRATED PRECLINICAL CAPABILITIES
Can’t Find Your Target in the HUGO-LAb™ Library?
Our antibody discovery platforms can support custom fully human antibody generation, from antibody discovery and screening to engineering and preclinical development.
Partner with HUGO-LAb™ from Target to Candidate
Flexible collaboration options support both joint development of high-value targets and selection of
validated antibody candidates for downstream therapeutic development.
Target Co-Development
Jointly develop fully human common light-chain and single-domain
antibodies for high-value therapeutic targets and next-generation antibody modalities.
Candidate Molecule Selection
Select high-quality antibody candidates through functional validation
and molecular characterization to support downstream development and collaboration.
What You Can Access Through HUGO-LAb™
Fully Human Ab sequences
Access selected fully human antibody sequences for downstream therapeutic
development.
Molecular Characterization Data
Review supporting molecular and functional data to evaluate candidate
potential.
Flexible Molecule Formats
Access fully human mAbs, common light-chain antibodies, and single-domain
antibody assets for multiple therapeutic modalities.
Licensing & Development Support
Advance selected molecules through licensing, engineering, optimization,
and downstream preclinical development.
Explore More Antibody Solutions
Supporting antibody discovery from fully human antibody generation to molecular engineering and
next-generation therapeutic development.
HUGO-Ab™ Fully Human Antibody Discovery Platform
An integrated platform combining fully human antibody mouse technologies
and antibody discovery capabilities to support diverse therapeutic antibody programs.
HUGO-Mab™ Fully Human Monoclonal Antibody Mouse
Generate fully human monoclonal antibody candidates directly in vivo for
therapeutic antibody discovery
HUGO-Light™ Common Light-Chain Antibody Platform
Explore dedicated BBB-focused antibody targets and model systems to
support CNS biologics delivery research.
HUGO-Nano™ Fully Human Single-Domain Antibody Platform
Discover compact, fully human heavy-chain-only single-domain antibodies
with enhanced access to sterically restricted and difficult-to-reach epitopes, enabling flexible
molecular engineering, improved tissue accessibility, and antibody discovery against challenging
targets.
HUGO-Ab-eKO™ Target-Knockout Antibody Discovery Platform
Enable antibody discovery against challenging or highly conserved targets
through target-knockout strategies that help overcome immune tolerance.
ADC Development
Advance ADC programs from antibody selection and characterization to
conjugation strategy and preclinical evaluation with integrated development support.
Target Details
{{ vars.target || "Consult Our Scientists" }}
Background
{{ vars.background }}
Interested in this target?
Contact our scientific team to discuss available models, development options, and supporting
data for your project.
Request the available target data package.
Depending on the target, supporting materials may include target background, model information, validation data, and recommended development options.
Depending on the target, supporting materials may include target background, model information, validation data, and recommended development options.
Phone Number
Project Interest
Project Details
Request a Preclinical CRO Services Consultation
Partner with Cyagen to advance your preclinical studies. Share your project goals with us and receive customized support.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
